Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:ADMS
Delisted

Adamas Pharmaceuticals Stock Price (Quote)

$8.22
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $8.22 $8.22 Friday, 27th May 2022 ADMS stock ended at $8.22. During the day the stock fluctuated 0% from a day low at $8.22 to a day high of $8.22.
90 days $8.22 $8.22
52 weeks $4.02 $8.25

Historical Adamas Pharmaceuticals prices

Date Open High Low Close Volume
Apr 04, 2016 $16.32 $16.32 $16.32 $16.32 245 109
Apr 01, 2016 $15.65 $15.65 $15.65 $15.65 354 591
Mar 31, 2016 $14.46 $14.46 $14.46 $14.46 272 742
Mar 30, 2016 $14.37 $14.37 $14.37 $14.37 210 761
Mar 29, 2016 $14.54 $14.54 $14.54 $14.54 304 100
Mar 28, 2016 $14.16 $14.16 $14.16 $14.16 503 500
Mar 24, 2016 $14.17 $14.17 $14.17 $14.17 255 000
Mar 23, 2016 $13.59 $13.59 $13.59 $13.59 276 800
Mar 22, 2016 $14.12 $14.12 $14.12 $14.12 280 400
Mar 21, 2016 $13.91 $13.91 $13.91 $13.91 526 200
Mar 18, 2016 $12.64 $12.64 $12.64 $12.64 487 200
Mar 17, 2016 $12.42 $12.42 $12.42 $12.42 516 500
Mar 16, 2016 $12.99 $12.99 $12.99 $12.99 178 600
Mar 15, 2016 $13.35 $13.35 $13.35 $13.35 297 500
Mar 14, 2016 $14.89 $14.89 $14.89 $14.89 245 800
Mar 11, 2016 $14.27 $14.27 $14.27 $14.27 226 600
Mar 10, 2016 $13.64 $13.64 $13.64 $13.64 238 500
Mar 09, 2016 $13.81 $13.81 $13.81 $13.81 315 000
Mar 08, 2016 $13.98 $13.98 $13.98 $13.98 410 400
Mar 07, 2016 $15.29 $15.29 $15.29 $15.29 358 000
Mar 04, 2016 $13.66 $13.66 $13.66 $13.66 436 300
Mar 03, 2016 $14.27 $14.27 $14.27 $14.27 352 000
Mar 02, 2016 $13.92 $13.92 $13.92 $13.92 234 800
Mar 01, 2016 $13.20 $13.20 $13.20 $13.20 275 500
Feb 29, 2016 $12.80 $12.80 $12.80 $12.80 357 500
Click to get the best stock tips daily for free!

About Adamas Pharmaceuticals

Adamas Pharmaceuticals Adamas Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The company’s lead product candidate is the ADS-5102 that is in Phase 3 clinical development for the treatment of levodopa-induced dyskinesia, a movement disorder associated with Parkinson’s disease; and in a Phase 2 clinical study for the treatment of symptoms assoc... ADMS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT